


Searching News Database: Par Pharmaceutical Companies
HSMN NewsFeed - 12 Nov 2014
Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)
Par Pharmaceutical Announces First FDA Approval of Vasostrict(TM) (vasopressin injection, USP)
HSMN NewsFeed - 22 Aug 2013
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical
HSMN NewsFeed - 20 Jan 2012
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
HSMN NewsFeed - 7 Jul 2010
MonoSol Rx Announces FDA Approval of Zuplenz(R) Oral Soluble Film for Treatment of Nausea and Vomiting
MonoSol Rx Announces FDA Approval of Zuplenz(R) Oral Soluble Film for Treatment of Nausea and Vomiting
HSMN NewsFeed - 4 Jun 2010
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
Par Pharmaceutical Announces the Resignation of Its Chief Financial Officer
HSMN NewsFeed - 18 Aug 2009
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
HSMN NewsFeed - 12 Jun 2009
Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Thomas P. Rice Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 10 Jun 2009
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
HSMN NewsFeed - 14 Oct 2008
Par Pharmaceutical Announces Resizing of Generic Unit to Optimize Strong First-to-File Pipeline
Par Pharmaceutical Announces Resizing of Generic Unit to Optimize Strong First-to-File Pipeline
HSMN NewsFeed - 7 May 2008
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
HSMN NewsFeed - 15 Jan 2008
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
HSMN NewsFeed - 31 Oct 2007
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
HSMN NewsFeed - 19 Jul 2007
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
Ortho-McNeil, Inc. Settles Patent Infringement Litigation Against Par/Kali
HSMN NewsFeed - 19 Jul 2007
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet(R) Patent Litigation
HSMN NewsFeed - 3 Jul 2007
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc(TM) From BioAlliance Pharma
HSMN NewsFeed - 12 Jun 2007
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
Immtech and Par Enter Licensing Agreement on Pafuramidine for Treatment of Pneumocystis Pneumonia
HSMN NewsFeed - 7 Jun 2007
Par Pharmaceutical Names Gerard A. Martino EVP and COO, Veronica A. Lubatkin EVP and CFO
Par Pharmaceutical Names Gerard A. Martino EVP and COO, Veronica A. Lubatkin EVP and CFO
HSMN NewsFeed - 8 Mar 2007
Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 26 Dec 2006
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
HSMN NewsFeed - 13 Nov 2006
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed - 26 Sep 2006
Patrick G. LePore Named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.
Patrick G. LePore Named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.
HSMN NewsFeed - 13 Sep 2006
Par Pharmaceutical Announces Agreement With Unimed Pharmaceuticals to Settle AndroGel(R) Patent Litigation
Par Pharmaceutical Announces Agreement With Unimed Pharmaceuticals to Settle AndroGel(R) Patent Litigation
HSMN NewsFeed - 30 Jun 2006
Par Pharmaceutical Receives Final Approval to Market Tranylcypromine Sulfate Tablets
Par Pharmaceutical Receives Final Approval to Market Tranylcypromine Sulfate Tablets
HSMN NewsFeed - 30 May 2006
Par Pharmaceutical Receives Final Approval to Market Polyethylene Glycol 3350 for Oral Solution
Par Pharmaceutical Receives Final Approval to Market Polyethylene Glycol 3350 for Oral Solution
HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Additional items found! 43
Members Archive contains
43 additional stories matching:
Par Pharmaceutical Companies
(Password required)
Par Pharmaceutical Companies
(Password required)
